Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
58163 Results Found
AHA expresses ‘profound concern’ about drug companies’ actions to undermine 340B program
The AHA sent letters to the heads of U.S. operations for five large drug companies — Merck, Eli Lilly, Sanofi, Novartis and AstraZeneca — expressing “profound concern” over actions they are taking to limit the distribution of certain 340B drugs to hospitals and health systems and asking them to “cease this conduct immediately.”
Advancing Racial Equity through Public Health Approaches to Community Violence August 19
Advancing Racial Equity through Public Health Approaches to Community Violence
HC3 Analyst Note TLP WHite: Thales Modules Vulnerability (CVE-2020-15858)
Researchers recently revealed an information about a vulnerability affecting the electronic chips that enable mobile communication in millions of internet connected devices.
Rural Health Services Special Edition Data Report HHS COVID-19, August 12, 2020
Thank you for your continued heroic work to care for your communities as our nation battles the COVID-19 pandemic.
Perspective: Recharging Our Caregivers for the Best Patient Care
August is traditionally the time to take a break, go on vacation, or just slow it down and relax for a bit. For many people, that’s off the table this year. COVID-19’s impact on health, our economy and our ability to gather in groups has been a game changer for people’s personal plans.
AHA expresses “profound concern” about drug companies’ actions to undermine 340B drug discount program
For more than 25 years, the 340B program has enabled hospitals that care for many low-income and uninsured patients to purchase certain outpatient drugs from drug companies at discounted prices
AHA to Eli Lilly and Company Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs
AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA to AztraZeneca Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs
AHA expresses profound concern about actions AztraZeneca is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA to Sanofi U.S./Sanofi Genzyme Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs
AHA expresses profound concern about actions Sanofi U.S./Sanofi Genzyme are taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA to Novartis Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs to Hospitals and Health Systems
AHA expresses profound concern about actions Novartis Corporation Global, is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.